You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

OPSUMIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Opsumit, and when can generic versions of Opsumit launch?

Opsumit is a drug marketed by Actelion and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in thirty-two countries.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the macitentan profile page.

DrugPatentWatch® Generic Entry Outlook for Opsumit

Opsumit was eligible for patent challenges on October 18, 2017.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (macitentan), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OPSUMIT?
  • What are the global sales for OPSUMIT?
  • What is Average Wholesale Price for OPSUMIT?
Drug patent expirations by year for OPSUMIT
Drug Prices for OPSUMIT

See drug prices for OPSUMIT

Recent Clinical Trials for OPSUMIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Janssen, LPPhase 4
American Heart AssociationPhase 4
Janssen Pharmaceutical K.K.Phase 3

See all OPSUMIT clinical trials

Pharmacology for OPSUMIT
Paragraph IV (Patent) Challenges for OPSUMIT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OPSUMIT Tablets macitentan 10 mg 204410 11 2017-10-18

US Patents and Regulatory Information for OPSUMIT

OPSUMIT is protected by five US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes 8,268,847 ⤷  Subscribe ⤷  Subscribe
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes 8,367,685 ⤷  Subscribe Y ⤷  Subscribe
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes 9,265,762 ⤷  Subscribe Y ⤷  Subscribe
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes 10,946,015 ⤷  Subscribe Y ⤷  Subscribe
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes 7,094,781 ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for OPSUMIT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Janssen-Cilag International N.V.   Opsumit macitentan EMEA/H/C/002697
Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.
Authorised no no yes 2013-12-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for OPSUMIT

When does loss-of-exclusivity occur for OPSUMIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2501
Patent: COMPOSICIONES TERAPEUTICAS
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 07290099
Patent: Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 0715698
Patent: produto, composiÇço farmacÊutica que o contÉm e uso de composto
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 59770
Patent: COMPOSITIONS THERAPEUTIQUES (THERAPEUTIC COMPOSITIONS)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 07002494
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UNA PIRIMIDINA TRISUSTITUIDA EN COMBINACION CON UN COMPUESTO CON PROPIEDADES INHIBITORIAS DE PDE5; Y USO EN EL TRATAMIENTO DE UNA ENFERMEDAD QUE INVOLUCRE VASOCONSTRICCION.
Estimated Expiration: ⤷  Subscribe

China

Patent: 1511365
Patent: Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0131233
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 14735
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 59246
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 59246
Patent: Compositions thérapeutiques comprenant une antagoniste spécifique pour les récepteurs à l'endothéline et un inhibiteur de la PDE5 (Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 33597
Patent: THERAPEUTIC COMPOSITIONS COMPRISING A SPECIFIC ENDOTHELIN RECEPTOR ANTAGONIST AND A PDE5 INHIBITOR
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 7235
Patent: תכשירים רפואיים ומוצר המכילים מרכיבים בעלי תכונות מעכבי pde5, ושימוש בהם ביצור תרופות (Therapeutic compositions and products comprising compounds having pde5-inhibitory properties and their use in the manufacture of medicaments)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 08113
Estimated Expiration: ⤷  Subscribe

Patent: 10502588
Estimated Expiration: ⤷  Subscribe

Malaysia

Patent: 4591
Patent: THERAPEUTIC COMPOSITIONS COMPRISING A SPECIFIC ENDOTHELIN RECEPTOR ANTAGONIST AND A PDE5 INHIBITOR
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 09002057
Patent: COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN UN ANTAGONISTA DEL RECEPTOR DE ENDOTELINA ESPECIFICO Y UN INHIBIDOR PDE5. (THERAPEUTIC COMPOSITIONS.)
Estimated Expiration: ⤷  Subscribe

Morocco

Patent: 704
Patent: COMPOSITIONS THERAPEUTIQUES
Estimated Expiration: ⤷  Subscribe

New Zealand

Patent: 5702
Patent: THERAPEUTIC COMPOSITIONS COMPRISING A SPECIFIC ENDOTHELIN RECEPTOR ANTAGONIST AND A PDE5 INHIBITOR
Estimated Expiration: ⤷  Subscribe

Norway

Patent: 2554
Estimated Expiration: ⤷  Subscribe

Patent: 091254
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 59246
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 59246
Estimated Expiration: ⤷  Subscribe

Russian Federation

Patent: 62249
Patent: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ РЕЦЕПТОРА ЭНДОТЕЛИНА И ИНГИБИТОР PDE5 (THERAPEUTIC COMPOSITIONS CONTAINING SPECIFIC ENDOTHELIN RECEPTOR ANTAGONIST AND PDE5 INHIBITOR)
Estimated Expiration: ⤷  Subscribe

Patent: 09111378
Patent: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ РЕЦЕПТОРА ЭНДОТЕЛИНА И ИНГИБИТОРОВ PDE5
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 59246
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 0902164
Patent: Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1473022
Estimated Expiration: ⤷  Subscribe

Patent: 090057009
Patent: THERAPEUTIC COMPOSITIONS
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 38792
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 88556
Estimated Expiration: ⤷  Subscribe

Patent: 0823198
Patent: Therapeutic compositions
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OPSUMIT around the world.

Country Patent Number Title Estimated Expiration
Morocco 30704 COMPOSITIONS THERAPEUTIQUES ⤷  Subscribe
Denmark 2059246 ⤷  Subscribe
Norway 20032699 ⤷  Subscribe
South Korea 100819668 ⤷  Subscribe
South Korea 101473022 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OPSUMIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1345920 SPC/GB14/018 United Kingdom ⤷  Subscribe PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220
1345920 14C0017 France ⤷  Subscribe PRODUCT NAME: MACITENTAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/893 20131220
1345920 132014902244514 Italy ⤷  Subscribe PRODUCT NAME: MACITENTAN(OPSUMIT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/893/001-002, 20131220
1345920 1490025-2 Sweden ⤷  Subscribe PRODUCT NAME: MACITENTAN; REG. NO/DATE: EU/1/13/893 20131220
1345920 CA 2014 00012 Denmark ⤷  Subscribe PRODUCT NAME: MACITENTAN OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/13/893 20131220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

OPSUMIT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Opsumit

Introduction

Opsumit, known generically as macitentan, is a pivotal drug in the treatment of Pulmonary Arterial Hypertension (PAH), a severe and progressive disease. Developed by Actelion, which is now part of Johnson & Johnson, Opsumit has been a market leader in the PAH treatment landscape since its FDA approval in December 2013.

Market Leadership and Sales Performance

Opsumit has consistently demonstrated strong sales performance, solidifying its position as a market leader in the PAH market. In 2020, Opsumit achieved blockbuster sales of $1,639 million, making it one of the highest-selling products in its class[1].

Clinical Trials and Label Expansions

Opsumit, along with another Johnson & Johnson product, Uptravi, is being investigated in clinical trials to support potential label expansions to chronic thromboembolic pulmonary hypertension (CTEPH). This expansion could significantly broaden the treatment options for CTEPH patients, who currently have limited approved therapies[1].

Competitive Landscape

The PAH market is highly competitive, with several drug classes vying for market share. However, Opsumit has maintained its dominance due to its efficacy and the strong patent portfolio held by Actelion. This portfolio, which includes 55% of the total patents for macitentan, poses significant challenges for generic drug manufacturers attempting to enter the market[4].

Drug Classes and Market Share

  • Endothelin Receptor Antagonists (ERAs): Historically, ERAs were the most commercially lucrative class, but they are now under threat from generics and the increasing use of prostacyclins in triple combination therapies[1].
  • Phosphodiesterase Type 5 Inhibitors (PDE5is): This class has faced fierce generic competition, leading to a significant decline in market share from $817 million in 2018 to $301 million in 2019[1].
  • Prostacyclins: This class has surpassed ERAs in sales, with total sales of $2,675 million in 2019 compared to $2,286 million for ERAs. Prostacyclins are expected to continue their growth trajectory, driven by their use in early polytherapy regimens[1].

Financial Performance

Initial Success

After its approval, Opsumit quickly gained traction. In the first quarter of 2015, it generated $99.5 million in sales, which rose to $390.2 million in the first half of 2016. This strong uptake was reflected in Actelion's financial performance, with product sales reaching CHF 1,008 million in the first half of 2015, driven largely by Opsumit's success[5].

Continued Growth

Actelion's financial reports highlighted the significant contribution of Opsumit to their revenue. By the end of June 2015, Opsumit had generated sales of 208 million Swiss francs, benefiting over 9,800 patients. This performance led to an upgrade in Actelion's financial guidance for the full year 2015[5].

Future Outlook

Market Growth Drivers

The PAH market is expected to continue growing, driven by label expansions into non-PAH subtypes and positive data on morbidity/mortality endpoints. Opsumit, along with other key products, is anticipated to play a crucial role in this growth, particularly as clinical trials support its use in broader patient populations[1].

Pipeline and Innovation

Johnson & Johnson's innovative medicine division, which includes Opsumit, is poised for robust growth. The company expects to deliver a compound annual growth rate (CAGR) of 5-7% from 2025 to 2030, driven by market share gains, new product launches, and expansions into new patient populations[3].

Challenges and Opportunities

Generic Competition

Despite the strong patent portfolio, the eventual expiration of patents will open the door to generic competition. However, the complexity of macitentan's formulation and the existing patent landscape will make it challenging for generic manufacturers to enter the market quickly[4].

Off-Label Use and Unmet Needs

The high rate of off-label use of PAH drugs for other forms of pulmonary hypertension (groups 2, 3, and 5) highlights a critical unmet need for approved therapies in these indications. Addressing these needs through label expansions and new clinical trials will be a key area of focus and growth for Opsumit and other PAH treatments[1].

Key Takeaways

  • Market Leadership: Opsumit is the established market leader in the PAH treatment market.
  • Strong Sales Performance: Opsumit achieved blockbuster sales of $1,639 million in 2020.
  • Clinical Trials and Label Expansions: Ongoing trials aim to expand Opsumit's label to include CTEPH.
  • Competitive Landscape: Opsumit faces competition from other drug classes, but its strong patent portfolio and efficacy maintain its market position.
  • Financial Performance: Opsumit has significantly contributed to Actelion's and Johnson & Johnson's financial success.
  • Future Outlook: The PAH market is expected to grow, driven by label expansions and positive clinical data.

FAQs

What is Opsumit used for?

Opsumit (macitentan) is used for the treatment of Pulmonary Arterial Hypertension (PAH), a severe and progressive disease.

How has Opsumit performed in the market?

Opsumit has been a market leader in the PAH treatment market, achieving blockbuster sales of $1,639 million in 2020.

What are the challenges for generic versions of Opsumit?

Generic manufacturers face challenges due to Actelion's strong patent portfolio, which includes 55% of the total patents for macitentan.

What are the future growth drivers for the PAH market?

The PAH market is expected to grow due to label expansions into non-PAH subtypes, positive data on morbidity/mortality endpoints, and the increasing use of prostacyclins in triple combination therapies.

How does Opsumit fit into Johnson & Johnson's overall strategy?

Opsumit is part of Johnson & Johnson's innovative medicine division, which is expected to drive robust growth through market share gains, new product launches, and expansions into new patient populations.

Sources

  1. Global Pulmonary Arterial Hypertension Market Report 2021 - Globenewswire
  2. Johnson & Johnson Reports Q4 and Full-Year 2023 Results - Johnson & Johnson Investor Relations
  3. Innovative Medicine Presentation - Johnson & Johnson
  4. Opsumit's Generic Drugs for PAH - A Hurdle before Pharma - GreyB
  5. ACTELION DELIVERS EXCELLENT FIRST HALF 2015 RESULTS - FiercePharma

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.